Nurix launches with Series B
Third Rock Ventures and The Column Group have backed the launch of Nurix with a $25.1 million Series B financing. Nurix develops therapies that modulate the ubiquitin proteasome system.
22 May 2014•4 mins read
Third Rock Ventures and The Column Group have backed the launch of Nurix with a $25.1 million Series B financing. Nurix develops therapies that modulate the ubiquitin proteasome system.
